Xoma Halts Development Of Acne Therapy XMP.629, Will Evaluate BPI Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Following disappointing Phase II results, Xoma will not conduct future trials with the bactericidal/permeability-increasing protein derivative XMP.629, its lead candidate. Earlier-stage BPI-derived products are under evaluation.